About Compass Pathways
We are unlocking pathways to be.
- Industry
- Mental Health Care
- Company size
- 51-200 employees
- Headquarters
- London, England
- Founded
- 2016
- Company type
- Public Company
We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care.
We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing.
We’re driven by our purpose of unlocking pathways to be - opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery.
Every journey needs a Compass.
Company locations
33 Broadwick Street, London, England W1F 0DQ, GB
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Wellness
- Biotechnology
- Life Science
- Mental Health
- Personal Health
- Biotech & Pharmaceuticals
- Pharmaceutical and biotechnology
On LinkedIn
- Followers
- 42,959
- People linked to this company
- 284
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
771,209,674 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.